More on Watson Pharmaceuticals (WPI) Q3: net profit +24% to $172.3M. Revenue breakdown: generics...
More on Watson Pharmaceuticals (WPI) Q3: net profit +24% to $172.3M. Revenue breakdown: generics +15%, brands +10%, distribution +44%. Increases FY guidance to $5.85-$5.95 for EPS and $5.9B for revenue vs consensus of $5.80 and $5.54B. For 2013, Watson expects adjusted EPS growth of 30%-40%. Has completed acquisition of Actavis, and will use that name from 2013.
From other sites
Video at CNBC.com (Thu, 5:00PM)
Video at CNBC.com (Sep 21, 2015)
Video at CNBC.com (Aug 6, 2015)
Video at CNBC.com (Jul 27, 2015)
at CNBC.com (Feb 18, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs